| 2026-08-04 | Transcript | Q4 FY24 earnings call transcript |
| 2026-08-04 | Press release | Exagen Inc. Reports Second Quarter 2026 Financial Results |
| 2026-08-04 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-04 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-07-28 | Press release | Exagen Inc. to Participate in Upcoming Investor Conference |
| 2026-07-21 | Press release | Exagen to Announce Second Quarter Financial Results on August 4, 2026 |
| 2026-06-09 | 8-K | Form 8-K, Item 5.07 |
| 2026-06-02 | Deck | Accelerating personalized medicine in autoimmune disease Q1 2026 UPDATE |
| 2026-06-01 | Press release | Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus |
| 2026-05-13 | Transcript | Q1 FY26 earnings call transcript |
| 2026-05-11 | Press release | Exagen Inc. Reports First Quarter 2026 Results |
| 2026-05-11 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-11 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-27 | Press release | Exagen Inc. to Announce First Quarter Financial Results on May 11, 2026 |
| 2026-04-27 | Proxy | Definitive proxy statement |
| 2026-04-23 | 8-K | Form 8-K, Item 5.02 |
| 2026-03-10 | Deck | Accelerating personalized medicine in autoimmune disease Q4 & FY 2025 UPDATE |
| 2026-03-10 | Press release | Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2025 Results |
| 2026-03-10 | 8-K | Form 8-K, Item 2.02 results |
| 2026-03-10 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-03-03 | Press release | Exagen Inc. to Participate in Upcoming Investor Conferences |
| 2026-02-24 | Press release | Exagen Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on March 10, 2026 |
| 2026-01-12 | 8-K | Form 8-K, Item 2.02 results |
| 2026-01-11 | Press release | Exagen Inc. Announces Select Preliminary 2025 Financial Results |
| 2025-11-04 | Press release | Exagen Inc. Reports Strong Q3 2025 Results |
| 2025-11-04 | 8-K | Form 8-K, Item 2.02 results |
| 2025-11-04 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-10-21 | Press release | Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 |
| 2025-07-30 | Transcript | Q2 FY25 earnings call transcript |
| 2025-07-29 | Press release | Exagen Inc. Reports Strong Q2 2025 Results |
| 2025-07-29 | 8-K | Form 8-K, Item 2.02 results |
| 2025-07-29 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2025-07-17 | 8-K | Form 8-K, Item 5.02 |
| 2025-07-15 | Press release | Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025 |
| 2025-06-11 | 8-K | Form 8-K, Item 5.07 |
| 2025-05-09 | 8-K | Form 8-K, Item 8.01 |
| 2025-05-08 | 8-K | Form 8-K, Item 1.01 |
| 2025-05-05 | Press release | Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume |
| 2025-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2025-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |